Immune checkpoint inhibitors (ICI) have been developed in gastric adenocarcinomas and approved in first-line metastatic setting (in combination with chemotherapy) as well as in pretreated patients. Microsatellite instability-high (MSI-H) tumors are predicted to derive high benefit from ICI but data in gastric locations are limited. Here, we describe the case of a 68-year old patient with stage IV MSI-H gastric adenocarcinoma, referred to our center to receive immunotherapy after failure of standard of care (surgery with perioperative platin-based chemotherapy and paclitaxel plus ramucirumab at disease progression). The patient received one injection of durvalumab and tremelimumab and was hospitalized eighteen days after because of occlusive syndrome. The CT scan showed hyperprogression of the lymph nodes and hepatic lesions, compressing the gastric stump. He died few days later. Molecular analyses did not explain this outcome. To our knowledge, this is one of the first reported cases of hyperprogressive disease after combined ICI for a patient with MSI-H tumor. We review the potential causes and discuss the emerging literature regarding predictive factors of hyperprogression in the particular subset of MSI-H patients. If some data were available in retrospective studies, validation of strong predictive factors is needed to avoid such dramatic evolutions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499695 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.756365 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature.
Discov Oncol
January 2025
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Article Synopsis
- Monotherapy with anti-PD-1 monoclonal antibodies has been approved for treating advanced non-small cell lung cancer with positive PD-L1 expression, showing better survival rates than chemotherapy.
- Certain patients experience hyperprogressive disease (HPD) despite this treatment, a phenomenon where cancer progresses rapidly, but the reasons and molecular traits behind it remain unclear.
- This study presents two cases of advanced lung adenocarcinoma with HER2 exon 20 insertion that developed HPD after anti-PD-1 treatment, suggesting this mutation could serve as a biomarker for avoiding ineffective immunotherapy in specific patients.
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD).
J Transl Med
January 2025
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Background: Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death worldwide. Although immune checkpoint inhibitors (ICIs) have shown remarkable clinical efficacy, they can also induce a paradoxical cancer acceleration, known as hyperprogressive disease (HPD), whose causative mechanisms are still unclear.
Methods: This study investigated the mechanisms of ICI resistance in an HPD-NSCLC model.
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer.
Sci Rep
December 2024
Department of Laboratory Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
Endometrial cancer is the most prevalent form of gynecologic malignancy, with a significant surge in incidence among youngsters. Although the advent of the immunotherapy era has profoundly improved patient outcomes, not all patients benefit from immunotherapy; some patients experience hyperprogression while on immunotherapy. Hence, there is a pressing need to further delineate the distinct immune response profiles in patients with endometrial cancer to enhance prognosis prediction and facilitate the prediction of immunotherapeutic responses.
View Article and Find Full Text PDFRisk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion.
World J Surg Oncol
November 2024
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Province, China.
Purpose: This study aimed to develop postsurgical progression/hyperprogression recurrence (type III-IV recurrence) prediction models for hepatocellular carcinoma (HCC) patients with macroscopic vascular invasion (MaVI) and to guide treatment strategies in the accurate healthcare era.
Patients And Methods: 393 HCC patients with MaVI from two central hospitals made up the entire study population. In developmental (290 patients) and validation (103 patients) cohorts, all patients were randomized into one or the other.
Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma.
Cancer Cell
December 2024
Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China; Innovation Center of the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510275, China. Electronic address:
Article Synopsis
- Hyperprogressive disease can occur in cancer patients on immune checkpoint blockade (ICB) therapy, revealing the complex interactions of immune cells in cancer progression.
- The study found that certain macrophages can present cancer antigens to CD103 cytotoxic T lymphocytes (CTLs), causing these CTLs to stay near tumors and activate inflammatory pathways that promote cancer growth and resistance to treatment.
- Analysis of HCC patients indicated that the accumulation of CD103 CTLs, despite their effector status, correlates with poor treatment outcomes, suggesting that modifying their distribution could improve ICB therapy effectiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!